Literature DB >> 21263161

Antioxidants in hypertension and cardiovascular disease.

Ernesto L Schiffrin1.   

Abstract

Cardiovascular disease is characterized by enhanced oxidative stress in the vascular wall, heart, kidney, and brain. Epidemiological evidence suggests that antioxidants, including vitamins C and E, α-carotene, and β-carotene, may be therapeutic; however, interventional trials of antioxidants have provided mixed results, with some showing deleterious consequences. It is thus crucial that we consider the implications of trial design and execution, and further investigation of cellular pro-and antioxidant mechanisms is critical. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and mineralocorticoid receptor blockers reduce the generation of reactive oxygen species, in experimental models as well as in humans, and have demonstrated beneficial cardiovascular effects. Polyphenols and antioxidants contained in foods and beverages may also be cardioprotective. Recent studies suggest that the judicious development of antioxidant agents may provide an effective approach to quench oxidative stress in tissues and improve cardiovascular health.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21263161     DOI: 10.1124/mi.10.6.4

Source DB:  PubMed          Journal:  Mol Interv        ISSN: 1534-0384


  29 in total

Review 1.  Disturbances in calcium metabolism and cardiomyocyte necrosis: the role of calcitropic hormones.

Authors:  Jawwad Yusuf; M Usman Khan; Yaser Cheema; Syamal K Bhattacharya; Karl T Weber
Journal:  Prog Cardiovasc Dis       Date:  2012 Jul-Aug       Impact factor: 8.194

Review 2.  Extracellular superoxide dismutase and its role in cancer.

Authors:  Brandon Griess; Eric Tom; Frederick Domann; Melissa Teoh-Fitzgerald
Journal:  Free Radic Biol Med       Date:  2017-08-24       Impact factor: 7.376

3.  Dopamine D1 and D5 receptors differentially regulate oxidative stress through paraoxonase 2 in kidney cells.

Authors:  S Yang; Y Yang; P Yu; J Yang; X Jiang; V A M Villar; D R Sibley; P A Jose; C Zeng
Journal:  Free Radic Res       Date:  2015-03-05

Review 4.  Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets.

Authors:  Grant R Drummond; Stavros Selemidis; Kathy K Griendling; Christopher G Sobey
Journal:  Nat Rev Drug Discov       Date:  2011-06       Impact factor: 84.694

5.  NOX2-derived reactive oxygen species in immune cells exacerbates salt-sensitive hypertension.

Authors:  Justine M Abais-Battad; Hayley Lund; John Henry Dasinger; Daniel J Fehrenbach; Allen W Cowley; David L Mattson
Journal:  Free Radic Biol Med       Date:  2019-11-12       Impact factor: 7.376

6.  Redox-regulated suppression of splenic T-lymphocyte activation in a model of sympathoexcitation.

Authors:  Adam J Case; Matthew C Zimmerman
Journal:  Hypertension       Date:  2015-02-17       Impact factor: 10.190

7.  Increased Levels of Modified Advanced Oxidation Protein Products Are Associated with Central and Peripheral Blood Pressure in Peritoneal Dialysis Patients.

Authors:  Hong Xu; Ivan Cabezas-Rodriguez; Abdul Rashid Qureshi; Olof Heimburger; Peter Barany; Sunna Snaedal; Björn Anderstam; Ann-Christin Bragfors Helin; Juan Jesus Carrero; Peter Stenvinkel; Bengt Lindholm
Journal:  Perit Dial Int       Date:  2014-03-01       Impact factor: 1.756

Review 8.  Reactive oxygen species, vascular Noxs, and hypertension: focus on translational and clinical research.

Authors:  Augusto C Montezano; Rhian M Touyz
Journal:  Antioxid Redox Signal       Date:  2013-06-06       Impact factor: 8.401

9.  Safety and adherence of Umezu polyphenols in the Japanese plum (Prunus mume) in a 12-week double-blind randomized placebo-controlled pilot trial to evaluate antihypertensive effects.

Authors:  Shigeki Takemura; Kouichi Yoshimasu; Jin Fukumoto; Kanae Mure; Nobuhiro Nishio; Kunihiro Kishida; Fumiko Yano; Takahiko Mitani; Tatsuya Takeshita; Kazuhisa Miyashita
Journal:  Environ Health Prev Med       Date:  2014-09-13       Impact factor: 3.674

Review 10.  Antioxidant-based therapies for angiotensin II-associated cardiovascular diseases.

Authors:  Erin G Rosenbaugh; Krupa K Savalia; Devika S Manickam; Matthew C Zimmerman
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-04-03       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.